Literature DB >> 21753797

Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

D H Aggen1, A S Chervin, T M Schmitt, B Engels, J D Stone, S A Richman, K H Piepenbrink, B M Baker, P D Greenberg, H Schreiber, D M Kranz.   

Abstract

Transduction of exogenous T-cell receptor (TCR) genes into patients' activated peripheral blood T cells is a potent strategy to generate large numbers of specific T cells for adoptive therapy of cancer and viral diseases. However, the remarkable clinical promise of this powerful approach is still being overshadowed by a serious potential consequence: mispairing of the exogenous TCR chains with endogenous TCR chains. These 'mixed' heterodimers can generate new specificities that result in graft-versus-host reactions. Engineering TCR constant regions of the exogenous chains with a cysteine promotes proper pairing and reduces the mispairing, but, as we show here, does not eliminate the formation of mixed heterodimers. By contrast, deletion of the constant regions, through use of a stabilized Vα/Vβ single-chain TCR (scTv), avoided mispairing completely. By linking a high-affinity scTv to intracellular signaling domains, such as Lck and CD28, the scTv was capable of activating functional T-cell responses in the absence of either the CD3 subunits or the co-receptors, and circumvented mispairing with endogenous TCRs. Such transduced T cells can respond to the targeted antigen independent of CD3 subunits via the introduced scTv, without the transduced T cells acquiring any new undefined and potentially dangerous specificities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753797      PMCID: PMC3321103          DOI: 10.1038/gt.2011.104

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  80 in total

Review 1.  Structural biology of the T-cell receptor: insights into receptor assembly, ligand recognition, and initiation of signaling.

Authors:  Kai W Wucherpfennig; Etienne Gagnon; Melissa J Call; Eric S Huseby; Matthew E Call
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03-17       Impact factor: 10.005

2.  T cell receptor CDR3 loops influence alphabeta pairing.

Authors:  Istvan Bartok; Stephen J Holland; Helmut W Kessels; Jonathan D Silk; Mooza Alkhinji; Julian Dyson
Journal:  Mol Immunol       Date:  2010-03-01       Impact factor: 4.407

3.  Selected murine residues endow human TCR with enhanced tumor recognition.

Authors:  Gil Bialer; Miryam Horovitz-Fried; Shlomo Ya'acobi; Richard A Morgan; Cyrille J Cohen
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

4.  Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.

Authors:  Timothy L Frankel; William R Burns; Peter D Peng; Zhiya Yu; Dhanalakshmi Chinnasamy; Jennifer A Wargo; Zhili Zheng; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2010-04-28       Impact factor: 5.422

5.  Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.

Authors:  Gavin M Bendle; Carsten Linnemann; Anna I Hooijkaas; Laura Bies; Moniek A de Witte; Annelies Jorritsma; Andrew D M Kaiser; Nadine Pouw; Reno Debets; Elisa Kieback; Wolfgang Uckert; Ji-Ying Song; John B A G Haanen; Ton N M Schumacher
Journal:  Nat Med       Date:  2010-04-18       Impact factor: 53.440

Review 6.  T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.

Authors:  Coen Govers; Zsolt Sebestyén; Miriam Coccoris; Ralph A Willemsen; Reno Debets
Journal:  Trends Mol Med       Date:  2010-02-01       Impact factor: 11.951

Review 7.  T cell receptor gene therapy for cancer.

Authors:  Thomas M Schmitt; Gunnar B Ragnarsson; Philip D Greenberg
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

8.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Authors:  Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-18       Impact factor: 22.113

9.  Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.

Authors:  A Hiasa; H Nishikawa; M Hirayama; S Kitano; S Okamoto; H Chono; S S Yu; J Mineno; Y Tanaka; N Minato; I Kato; H Shiku
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

10.  The impact of TCR-binding properties and antigen presentation format on T cell responsiveness.

Authors:  Adam S Chervin; Jennifer D Stone; Phillip D Holler; Ailin Bai; Jianzhu Chen; Herman N Eisen; David M Kranz
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

View more
  26 in total

1.  Tumor immunology: multidisciplinary science driving basic and clinical advances.

Authors:  Bridget P Keenan; Elizabeth M Jaffee; Todd D Armstrong
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 2.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

3.  TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.

Authors:  Timothy T Spear; Kendra C Foley; Elizabeth Garrett-Mayer; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2018-01-19       Impact factor: 4.962

4.  Specific roles of each TCR hemichain in generating functional chain-centric TCR.

Authors:  Munehide Nakatsugawa; Yuki Yamashita; Toshiki Ochi; Shinya Tanaka; Kenji Chamoto; Tingxi Guo; Marcus O Butler; Naoto Hirano
Journal:  J Immunol       Date:  2015-02-20       Impact factor: 5.422

5.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

Review 6.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

7.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Authors:  Jennifer D Stone; Daniel T Harris; Carolina M Soto; Adam S Chervin; David H Aggen; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2014-08-01       Impact factor: 6.968

Review 8.  Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.

Authors:  Daniel T Harris; David M Kranz
Journal:  Trends Pharmacol Sci       Date:  2015-12-17       Impact factor: 14.819

9.  Molecular insights for optimizing T cell receptor specificity against cancer.

Authors:  Michael Hebeisen; Susanne G Oberle; Danilo Presotto; Daniel E Speiser; Dietmar Zehn; Nathalie Rufer
Journal:  Front Immunol       Date:  2013-06-19       Impact factor: 7.561

Review 10.  CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More.

Authors:  Xuejin Ou; Qizhi Ma; Wei Yin; Xuelei Ma; Zhiyao He
Journal:  Front Cell Dev Biol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.